GMAB
Genmab A/SNASDAQHealthcare$27.50+1.03%ClosedMarket Cap: $16.98B
As of 2026-04-06
Valuation
P/E (TTM)
6.15
PEG
—
P/B
2.85
P/S
0.90
EV/EBITDA
3.80
DCF Value
$6.01
FCF Yield
17.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.0%
Operating Margin
36.7%
Net Margin
21.0%
ROE
19.0%
ROA
114.7%
ROIC
50.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.05B | 92.3% | $242.3M | $30.9M | $0.05 | — |
| FY 2025 | $3.72B | 91.7% | $1.25B | $963.8M | $1.54 | — |
| Q3 2025 | $1.02B | 94.3% | $459.0M | $401.0M | $0.65 | — |
| Q2 2025 | $5.86B | 93.8% | $2.28B | $2.13B | $3.42 | — |
| Q1 2025 | $715.0M | 94.1% | $188.0M | $195.0M | $0.31 | — |
| Q4 2024 | $6.44B | 94.8% | $2.16B | $3.85B | $5.99 | — |
| FY 2024 | $21.53B | 95.4% | $6.70B | $7.84B | $12.14 | — |
| Q3 2024 | $5.54B | 95.1% | $2.10B | $1.27B | $1.95 | — |
| Q2 2024 | $779.0M | 96.4% | $236.0M | $203.0M | $2.17 | — |
| Q1 2024 | $603.0M | 95.5% | $116.0M | $192.0M | $2.02 | — |
| Q4 2023 | $4.68B | 97.3% | $1.67B | $640.0M | $0.97 | — |
| FY 2023 | $16.47B | 98.6% | $5.32B | $4.35B | $6.60 | — |